Sekar Kathiresan M.D.
Net Worth

Last updated:

What is Sekar Kathiresan M.D. net worth?

The estimated net worth of Dr. Sekar Kathiresan M.D. is at least $17,667,055 as of 28 Jun 2024. He owns shares worth $3,559,797 as insider, has earned $11,219,298 from insider trading and has received compensation worth at least $2,887,960 in Verve Therapeutics, Inc..

What is the salary of Sekar Kathiresan M.D.?

Dr. Sekar Kathiresan M.D. salary is $721,990 per year as Co-Founder, Chief Executive Officer & Director in Verve Therapeutics, Inc..

How old is Sekar Kathiresan M.D.?

Dr. Sekar Kathiresan M.D. is 53 years old, born in 1972.

What stocks does Sekar Kathiresan M.D. currently own?

As insider, Dr. Sekar Kathiresan M.D. owns shares in one company:

Company Title Shares Price per share Total value
Verve Therapeutics, Inc. (VERV) Co-Founder, Chief Executive Officer & Director 317,839 $11.2 $3,559,797

What does Verve Therapeutics, Inc. do?

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV logo
VERV
Verve Therapeutics, Inc.
$11.2

Sekar Kathiresan M.D. insider trading

Verve Therapeutics, Inc.

Dr. Sekar Kathiresan M.D. has made 10 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 114,000 units of VERV stock on 23 Dec 2021. As of 28 Jun 2024 he still owns at least 317,839 units of VERV stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 30,000 $2.87 $86,100
Option
Stock Option (right to buy) 30,000 $2.87 $86,100
Option
Stock Option (right to buy) 50,000 $1.39 $69,500
Option
Common Stock 50,000 $1.39 $69,500
Sale
Common Stock 28,911 $33.02 $954,526
Sale
Common Stock 11,185 $34.13 $381,744
Sale
Common Stock 9,904 $34.97 $346,363
Sale
Common Stock 50,000 $29.9 $1,495,000
Option
Common Stock 50,000 $1.39 $69,500
Option
Stock Option (right to buy) 50,000 $1.39 $69,500
Sale
Common Stock 50,000 $29.9 $1,495,000
Option
Common Stock 50,000 $1.39 $69,500
Option
Stock Option (right to buy) 50,000 $1.39 $69,500
Option
Common Stock 69,674 $2.87 $199,964
Option
Stock Option (right to buy) 69,674 $2.87 $199,964
Option
Stock Option (right to buy) 1,870 $1.39 $2,599
Option
Common Stock 1,870 $1.39 $2,599
Sale
Common Stock 1,870 $39.9 $74,613
Sale
Common Stock 6,693 $39.9 $267,051
Option
Stock Option (right to buy) 48,693 $1.39 $67,683
Option
Common Stock 6,693 $1.39 $9,303
Option
Common Stock 42,000 $1.39 $58,380
Sale
Common Stock 42,000 $41.16 $1,728,678
Option
Common Stock 57,000 $1.39 $79,230
Option
Stock Option (right to buy) 114,000 $1.39 $158,460
Sale
Common Stock 57,000 $39.9 $2,274,300
Sale
Common Stock 57,000 $38.63 $2,202,024
Option
Common Stock 57,000 $1.39 $79,230
Purchase
Common Stock 2,500 $19 $47,500

Verve Therapeutics key executives

Verve Therapeutics, Inc. executives and other stock owners filed with the SEC: